Seal Rock Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Seal Rock Therapeutics's estimated annual revenue is currently $1.4M per year.
- Seal Rock Therapeutics's estimated revenue per employee is $199,286
Employee Data
- Seal Rock Therapeutics has 7 Employees.
- Seal Rock Therapeutics grew their employee count by 0% last year.
Seal Rock Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Director Chemistry | Reveal Email/Phone |
Seal Rock Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 5 | 0% | N/A | N/A |
#2 | $0.9M | 5 | 0% | N/A | N/A |
#3 | $5.1M | 30 | 11% | N/A | N/A |
#4 | $5.7M | 37 | 42% | N/A | N/A |
#5 | $1.4M | 18 | -10% | N/A | N/A |
#6 | $3.7M | 41 | 5% | $16M | N/A |
#7 | $1.1M | 11 | 83% | N/A | N/A |
#8 | $0.8M | 5 | -81% | N/A | N/A |
#9 | $2.5M | 16 | -27% | N/A | N/A |
#10 | $0.8M | 8 | 100% | N/A | N/A |
What Is Seal Rock Therapeutics?
Seal Rock Therapeutics, Inc. is discovering and developing small molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1), a protein that mediates apoptosis, inflammation, and fibrosis. Seal Rock is currently focusing its efforts on hepatic indications including NASH (non-alcoholic steatohepatitis), a condition resulting from fatty liver disease, characterized by hepatic inflammation and cellular damage that lead to liver fibrosis. Additional opportunities with ASK1 inhibitors include cardiac, immunological and neurodegenerative indications.
keywords:N/A
N/A
Total Funding
7
Number of Employees
$1.4M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Seattle
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.5M | 7 | N/A | N/A |
#2 | $0.1M | 7 | -22% | $42.7M |
#3 | $0.5M | 7 | N/A | N/A |
#4 | $0.9M | 7 | N/A | N/A |
#5 | $3.5M | 7 | 40% | N/A |